Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer

Document Type : Original Article


1 Dubai Nuclear Medicine and Molecular imaging Center-Dubai Health Authority, Dubai, UAE

2 Department of Pathology and Genetics, Dubai Hospital, Dubai Health Authority, Dubai, UAE

3 Department of urology-Dubai Health Authority, Dubai, UAE

4 Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran


Objective(s): 99mTc-PSMA SPECT/CT is a cost effective alternative for 68Ga-PSMA PET/CT. The aim of this study was to directly compare these two techniques in patients with prostate cancer.
Methods: 28 man with prostate cancer were studied using 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in a short time period (68Ga-PSMA. 99mTc-PSMA kit (PSMA I+S) was used for SPECT/CT and whole body imaging was performed 4 hours after IV injection of 740 MBq of 99mTc-PSMA.  Images were interpreted independently and the results of each imaging were recorded.
Results: The mean age of the patients was 64.7±9.6 years old and the mean time difference between two sets of images was 16.6±13.5 days. Abnormal uptake was seen in 25 (89.2%) patients by 68Ga-PSMA PET/CT and 20 (71.4%) patients with 99mTc-PSMA SPECT/CT. No patients with positive 99mTc-PSMA SPECT/CT had negative 68Ga-PSMA PET/CT. The mean number of detected lesions was 26.07±27.5 by 68Ga-PSMA PET/CT and 10.52±10.99 by 99mTc-PSMA SPECT/CT (P<0.001). Detection of lymph nodes and bone metastases were not significantly different between two sets of imaging (P>0.05), however 68Ga-PSMA PET/CT were more successful in detection of prostate bed lesions compared to 99mTc-PSMA scan. Interestingly, no patient with PSA level of >2.1 ng/ml had discordant result between two sets of images.
Conclusion: 99mTc-PSMA SPECT/CT is as accurate as  68Ga-PSMA PET/CT in M staging, however 68Ga-PSMA PET/CT detected more lesions compared to 99mTc-PSMA SPECT/CT. Detection rate was not significantly different between two techniques in patients with PSA levels>2.1 ng/ml.


1. Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. Jama. 2017 Jun 27; 317(24):2532-42.
2. Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2013 Jun; 54(6):833-40.
3. Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, et al. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2016 Oct; 57(Suppl 3):79S-89S.
4. Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA Theranostics: Current Status and Future Directions. Molecular imaging. 2018 Jan-Dec; 17:1536012118776068.
5. Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, et al. Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617. European journal of nuclear medicine and molecular imaging. 2018 Jan; 45(1):31-7.
6. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2015 Nov; 56(11):1697-705.
7. Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, et al. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013 Dec; 22(12):2354-63.
8. Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, et al. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2017 Feb; 58(2):235-42.
9. Su HC, Zhu Y, Hu SL, Liu C, Lin GW, Dai B, et al. The Value of (99m) Tc-PSMA SPECT/CT-Guided Surgery for Identifying and Locating Lymph Node Metastasis in Prostate Cancer Patients. Annals of surgical oncology. 2019 Feb; 26(2):653-9.
10. Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM. Diagnostic sensitivity of 99m Tc- HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with 68Ga- PSMA PET/CT. The Prostate. 2017 Aug; 77(11):1205-12.
11. Garcia-Perez FO, Davanzo J, Lopez-Buenrostro S, Santos-Cuevas C, Ferro-Flores G, Jimenez-Rios MA, et al. Head to head comparison performance of (99m)Tc-EDDA/HYNIC-iPSMA SPECT/CT and (68)Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients. American journal of nuclear medicine and molecular imaging. 2018; 8(5):332-40.
12. Janssen JC, Meissner S, Woythal N, Prasad V, Brenner W, Diederichs G, et al. Comparison of hybrid (68)Ga-PSMA-PET/CT and (99m)Tc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT. European radiology. 2018 Feb; 28(2):610-9.
13. Thomas L, Balmus C, Ahmadzadehfar H, Essler M, Strunk H, Bundschuh RA. Assessment of Bone Metastases in Patients with Prostate Cancer-A Comparison between (99m) Tc-Bone-Scintigraphy and [(68) Ga] Ga-PSMA PET/CT. Pharmaceuticals (Basel, Switzerland). 2017 Jul 31; 10(3).
14. Langsteger W, Rezaee A, Pirich C, Beheshti M. (18)F-NaF-PET/CT and (99m)Tc-MDP Bone Scintigraphy in the Detection of Bone Metastases in Prostate Cancer. Seminars in nuclear medicine. 2016 Nov; 46(6):491-501.
15. Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E, et al. 68Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli? Clinical genitourinary cancer. 2018 2018/10/01/; 16(5):392-401.
16. Su HC, Zhu Y, Ling GW, Hu SL, Xu XP, Dai B, et al. Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse. Asian journal of andrology. 2017 May-Jun; 19(3):267-71.
17. Wong HS, Leung J, Bartholomeusz D, Sutherland P, Le H, Nottage M, et al. Comparative study between (68) Ga-prostate-specific membrane antigen positron emission  tomography and conventional imaging in the initial staging of prostate cancer. Journal of medical imaging and radiation oncology. 2018 Dec; 62(6):816-22.
18. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of Hybrid (6)(8)Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2015 May; 56(5):668-74.
19. Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. European urology. 2016 Dec; 70(6):926-37.
20. Natarajan A, Agrawal A, Murthy V, Bakshi G, Joshi A, Purandare N, et al. Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients. World journal of nuclear medicine. 2019 Jul-Sep; 18(3):244-50.
21. Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, et al. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2016 Nov; 57(11):1713-9.
22. Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. European journal of nuclear medicine and molecular imaging. 2017 Jun; 44(6):1014-24.